**Freedom of Information Act 2000 - Request Reference FoI/23/508**
**Coagulation Factors**

1. In the last 3 months (July, August, and September 2023), how many Haemophilia A, Haemophilia B and von Willebrand patients were treated in your trust with the following coagulation factors:

1) Hemlibra (non-inhibitor patients)
a. VWD - 0
b. Haem A - 0
c. Haem B - 0
2) Hemlibra (inhibitor patients)
a. VWD - 0
b. Haem A - 0
c. Haem B - 0
3) Advate
a. VWD - *
b. Haem A - 17
c. Haem B - 0
4) Adynovi
a. VWD - 0
b. Haem A - 0
c. Haem B - 0
5) Elocta
a. VWD - 0
b. Haem A - 6
c. Haem B - 0
6) Esperoct
a. VWD - 0
b. Haem A - 10
c. Haem B - 0
7) NovoEight
a. VWD - 0
b. Haem A - 0
c. Haem B - 0
8) ReFacto AF
a. VWD - 0
b. Haem A - 0
c. Haem B - 0
9) Nuwiq
a. VWD - 0
b. Haem A - 0
c. Haem B - 0
10) Idelvion
a. VWD - 0
b. Haem A - 0
c. Haem B - *
11) Refixia
a. VWD - 0
b. Haem A - 0
c. Haem B - *
12) Alprolix
a. VWD - 0
b. Haem A - 0
c. Haem B - *
13) BeneFIX
a. VWD - 0
b. Haem A - 0
c. Haem B - *
14) Replenine
a. VWD - 0
b. Haem A - 0
c. Haem B - 0
15) Rixubis
a. VWD - 0
b. Haem A - 0
c. Haem B - *
16) Voncento
a. VWD - *
b. Haem A - 0
c. Haem B - 0
17) Veyvondi
a. VWD - *
b. Haem A - 0
c. Haem B - 0
18) Wilate
a. VWD - 0
b. Haem A - 0
c. Haem B - 0
19) Willfact
a. VWD - 0
b. Haem A - 0
c. Haem B - 0
20) Alphanate
a. VWD - 0
b. Haem A - 0
c. Haem B - 0
21) Octanate
a. VWD - 0
b. Haem A - 0
c. Haem B - 0
22) Optivate
a. VWD - 0
b. Haem A - 0
c. Haem B - 0
23) Fahndi
a. VWD - 0
b. Haem A - 0
c. Haem B - 0
24) Haemate
a. VWD - 0
b. Haem A - 0
c. Haem B - 0

Please note that Section 40 of the Freedom of Information Act 2000 has been applied where information in the above table has been replaced with an asterisk. The UHB will not provide these exact numbers due to the low numbers of individuals involved (5 or less). The UHB believes there is a potential risk of individuals being able to be identified, when considered with other information already available within the public domain, if this was disclosed. Therefore, the data is classed as personal data as defined under the General

Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

2. In the last 3 months (July, August, and September 2023), how much volume in IU or mg was used of the following coagulation factors:

a. Hemlibra (non-inhibitor patients) - 42315 mg – please note that the UHB is unable to determine the separate categories of patient at Pharmacy level, therefore this figure represents non-inhibitor patients and inhibitor patients.
b. Hemlibra (inhibitor patients) - as above.
c. Advate - 416000 Units
d. Adynovi - 0 Units
e. Elocta - 108500 Units
f. Esperoct - 136000 Units
g. NovoEight - 0 Units
h. ReFacto AF - 6000 Units
i. Nuwiq - 0 Units
j. Idelvion - 73000 Units
k. Refixia - 40000 Units
l. Alprolix - 34000 Units
m. BeneFIX - 37500 Units
n. Replenine - 0 Units
o. Rixubis - 12000 Units
p. Voncento - 63000 Units
q. Veyvondi - 105300 Units
r. Wilate - 0 Units
s. Willfact - 0 Units
t. Alphanate - 0 Units
u. Octanate - 0 Units
v. Optivate - 0 Units
w. Fahndi - 0 Units
x. Haemate - 0 Units

3. In the last 3 months (July, August, and September 2023), how many patients switched from one of the following products to any other brand? Please indicate the brand that was switched to (i.e. Advate: 2 switches to Hemlibra, 3 switches to Elocta)

a. Hemlibra (non-inhibitor patients)
b. Hemlibra (inhibitor patients)
c. Advate
d. Adynovi
e. Elocta
f. Esperoct
g. NovoEight
h. ReFacto AF
i. Nuwiq
j. Idelvion
k. Refixia
l. Alprolix
m. BeneFIX
n. Replenine
o. Rixubis
p. Voncento

q. Veyvondi
r. Wilate
s. Willfact
t. Alphanate
u. Octanate
v. Optivate
w. Fahndi
x. Haemate

After considering your request, the UHB believes that the data requested is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.